Syndivia and Biofunctional Chemistry Laboratory announce publication of a review titled “Antibody–Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents” in Bioconjugate Chemistry. The review gives a comprehensive overview of the main applications of antibody-oligonucleotide conjugates (AOC) as well as major synthetic approaches used for their preparation. The review emphasized the importance of the development of novel methods for efficient and reliable generation of AOC, in order to advance their new applications.
Syndivia will be attending the 2019 BIO International Convention that takes place in Philadelphia, PA, USA, on 3-6 June 2019. Contact us on firstname.lastname@example.org, or via the partneringONE® platform to request a meeting and discuss exciting new opportunities in the biopharmaceutical space.
Syndivia’s CSO, Dr Sergii Kolodych, will present our latest developments at PEGS Summit 2019.
April 8-12, Seaport World Trade Center, Boston, MA.
Syndivia’s CSO, Dr Sergii Kolodych, will be presenting ENACT technology and its application for native protein modification at PEGS Europe 2018, November 12-16, 2018, Lisbon, Portugal.
Syndivia will be attending BIO-Europe® that takes place in Copenhagen, Denmark, on 5-7 November 2018. Contact us on email@example.com, or via the partneringONE® platform to request a meeting and discuss exciting new opportunities in the biopharmaceutical space.
Syndivia’s CEO, Dr Oleksanr Koniev, will be giving a talk at MedFIT 2018, Strasbourg, France, on Wednesday, 27th June 2018. MedFIT is the leading European partnering event dedicated to innovation partnerships and the main marketplace for early-stage investment in the fields of medical technology, diagnostic and digital health.
Düsseldorf, Germany, December 12, 2017 -- Syndivia receives a winning award at the European Venture Contest Final as one of the top 20 companies, selected from over 1250+ applications and 600+ pitches held throughout the Tech Tour 2017. Official press-release: view online here
PARIS, France, February 2, 2017 -- Syndivia wins the France Tech Transfer Invest Award during a Tech Tour event that took place in Paris on 1-2 February 2017. The event is a collaboration between the SATT, Tech Tour, Bpifrance and its EuroQuity platform and aims to efficiently and effectively support French tech companies to meet and engage with international investors and corporate partners.
For more information on the event visit: http://techtour.com/events/view.aspx?events_pages_id=7749
NANTES, France, Sept. 6, 2016 (GLOBE NEWSWIRE) -- OGD2 Pharma SAS, a biotechnology company developing innovative anti-cancer therapies targeting the O-acetylated form of the GD2 ganglioside (OAcGD2), today announces a collaboration with Syndivia SAS, a biotechnology company that provides best-in-class bioconjugation technologies for the development of Antibody-Drug Conjugates (ADC).
Full press release available at: http://globenewswire.com/news-release/2016/09/06/869521/10164974/en/OGD2-Pharma-and-Syndivia-launch-collaboration-to-develop-an-ADC-targeting-the-O-acetyl-GD2-cancer-antigen.html